Drug Search Results
More Filters [+]

Etrolizumab

Alternative Names: etrolizumab, rhumab beta7, Etrozulimab, RO5490261, RG7413, RO-5490261, RG-7413
Latest Update: 2024-05-09
Latest Update Note: PubMed Publication

Product Description

Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn's disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined patient populations in rigorous trials that include direct head-to-head comparisons against approved anti-tumor necrosis factor alpha agents (anti-TNF). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32445184/)

Mechanisms of Action: ITGA4-B7 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Etrolizumab

Countries in Clinic:

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Colitis, Ulcerative

Phase 1: Crohn Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Lantana

P3

Active, not recruiting

Colitis, Ulcerative

2024-01-23

2017-003649-10

P1

Active, not recruiting

Colitis, Ulcerative|Crohn Disease

2023-03-08

Recent News Events